Who are Experimental: Tralokinumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo to dupilumab, Tralokinumab + TCS, GSK1358820.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/experimental-tralokinumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Experimental: Tralokinumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Experimental: Tralokinumab (Experimental: Tralokinumab) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody; IL-13 inhibitor. Area: Immunology; Dermatology.

phase 3 Monoclonal antibody; IL-13 inhibitor IL-13 (Interleukin-13) Immunology; Dermatology Biologic Live · refreshed every 30 min

Target snapshot

Experimental: Tralokinumab (Experimental: Tralokinumab) — AstraZeneca. Tralokinumab is a monoclonal antibody that blocks interleukin-13 (IL-13), a key cytokine driving type 2 inflammatory responses.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Experimental: Tralokinumab TARGET	Experimental: Tralokinumab	AstraZeneca	phase 3	Monoclonal antibody; IL-13 inhibitor	IL-13 (Interleukin-13)
Placebo to dupilumab	Placebo to dupilumab	AbbVie	phase 3	IL-4/IL-13 inhibitor	IL-4Rα
Tralokinumab + TCS	Tralokinumab + TCS	LEO Pharma	phase 3	IL-13 inhibitor	IL-13
GSK1358820	GSK1358820	GlaxoSmithKline	phase 3	IL-13 inhibitor monoclonal antibody	IL-13

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody; IL-13 inhibitor class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Experimental: Tralokinumab — Competitive Intelligence Brief. https://druglandscape.com/ci/experimental-tralokinumab. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing